Maker of latest experimental vaccine not expected to seek authorization until June at the earliest
Maker of latest experimental vaccine not expected to seek authorization until June at the earliest Carolyn Y. Johnson © Dado Ruvic/Reuters The coronavirus vaccine being made by Novavax would represent the first shot the company has brought to market if regulatory approvals are secured. (Dado Ruvic/Reuters) A 34-year-old Maryland biotechnology company that has never successfully launched a vaccine faces a world impatient for more coronavirus shots to quell a pandemic — but the wait isn’t over. Novavax, bolstered by $1.6 billion in federal funding, is unlikely to see...